Paul Hebeisen

1.2k citations

39 papers · 968 indexed · h-index 17

Co-authors: Peter Angehrn Rudolf Then Malcolm G. P. Page Ingrid Heinze‐Krauss P. Hohl Matthias P. Wymann Florent Beaufils Chiara Borsari
Topics: PI3K/AKT/mTOR signaling in cancer (10 papers)Synthesis and Biological Evaluation (6 papers)Cancer therapeutics and mechanisms (5 papers)
Cited by: Molecular Medicine Organic Chemistry Toxicology
Journals: Journal of the American Chemical Society Blood Cancer Research
Partner nations: Switzerland Austria Germany

In The Last Decade

Paul Hebeisen

39 papers receiving 931 citations

Peers

Countries citing papers authored by Paul Hebeisen

Since Specialization

Citations

This map shows the geographic impact of Paul Hebeisen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Hebeisen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Hebeisen more than expected).

Fields of papers citing papers by Paul Hebeisen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Hebeisen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Hebeisen. The network helps show where Paul Hebeisen may publish in the future.

Co-authorship network of co-authors of Paul Hebeisen

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Hebeisen. A scholar is included among the top collaborators of Paul Hebeisen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Hebeisen. Paul Hebeisen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor 2022 ·European Journal of Medicinal Chemistry ·(unknown),(unknown),Chiara Tarantelli,Florent Beaufils,Alessandro Prescimone,(unknown),(unknown),(unknown),Luka Raguž,Thorsten Schaefer,Paul Hebeisen,Francesco Bertoni,Matthias P. Wymann,Chiara Borsari	11
2	Stereospecific Synthesis of Substituted Sulfamidates as Privileged Morpholine Building Blocks 2022 ·Synthesis ·(unknown),Claudio F. Meyer,Pierre Boulay,Matthias P. Wymann,Chiara Borsari,Paul Hebeisen,Denise Rageot	1
3	Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability 2021 ·RSC Medicinal Chemistry ·Chiara Borsari,Erhan Keleş,(unknown),(unknown),Paul Hebeisen,Matthias Hamburger,Matthias P. Wymann	8
4	4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders 2020 ·Journal of Medicinal Chemistry ·Chiara Borsari,Erhan Keleş,Denise Rageot,(unknown),Thomas Bohnacker,(unknown),(unknown),Anna Melone,Rohitha Sriramaratnam,Florent Beaufils,Matthias Hamburger,Paul Hebeisen,Wolfgang Löscher,Doriano Fabbro,Petra Hillmann,Matthias P. Wymann	18
5	A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor 2019 ·Journal of Medicinal Chemistry ·Chiara Borsari,Denise Rageot,(unknown),Thomas Bohnacker,Anna Melone,Alexander Sele,(unknown),Jean‐Baptiste Langlois,Florent Beaufils,Paul Hebeisen,Doriano Fabbro,Petra Hillmann,Matthias P. Wymann	30
6	Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors 2019 ·Organic Process Research & Development ·Denise Rageot,Florent Beaufils,Chiara Borsari,(unknown),Markus Neuburger,Paul Hebeisen,Matthias P. Wymann	7
7	(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase 2019 ·Journal of Medicinal Chemistry ·Denise Rageot,Thomas Bohnacker,Erhan Keleş,Jacob A. McPhail,Reece M. Hoffmann,Anna Melone,Chiara Borsari,Rohitha Sriramaratnam,Alexander Sele,Florent Beaufils,Paul Hebeisen,Doriano Fabbro,Petra Hillmann,John E. Burke,Matthias P. Wymann	49
8	Molecular Structure and Crystal Packing of Monofluoromethoxyarenes 2017 ·European Journal of Organic Chemistry ·Paul Hebeisen,(unknown),André Alker,Bernd Kuhn,Klaus Müller,Fang Wang,G. K. Surya Prakash	8
9	5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology 2017 ·Journal of Medicinal Chemistry ·Florent Beaufils,(unknown),Vladimir Cmiljanović,Thomas Bohnacker,Anna Melone,Romina Marone,(unknown),Xuxiao Zhang,Alexander Sele,Chiara Borsari,Jürgen Mestan,Paul Hebeisen,Petra Hillmann,Bernd Giese,Marketa Zvelebil,Doriano Fabbro,Roger Williams,Denise Rageot,Matthias P. Wymann	115
10	Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase 2011 ·Bioorganic & Medicinal Chemistry Letters ·Paul Hebeisen,Wolfgang Haap,Bernd Kuhn,Peter J. Mohr,Hans Peter Wessel,Ulrich Zutter,Stephan Kirchner,A. Ruf,Jörg Benz,Catherine Joseph,Rubén Alvarez‐Sánchez,Marcel Gubler,Brigitte Schott,Agnès Bénardeau,Effie Tozzo,Eric Kitas	14
11	Ring opening of cyclic sulfamidates with bromophenyl metal reagents: complementarity of sulfamidates and aziridines 2011 ·Tetrahedron Letters ·Paul Hebeisen,(unknown),André Alker,Andreas Staempfli	17
12	Enantioselective desymmetrizing palladium catalyzed carbonylation reactions: the catalytic asymmetric synthesis of quaternary carbon center containing 1,3-dienes 2009 ·Organic & Biomolecular Chemistry ·(unknown),Anthony Fletcher,Paul Hebeisen,Michael C. Willis	15
13	Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of Type-2 diabetes 2009 ·Bioorganic & Medicinal Chemistry Letters ·Eric Kitas,Peter J. Mohr,Bernd Kuhn,Paul Hebeisen,Hans Peter Wessel,Wolfgang Haap,A. Ruf,Jörg Benz,Catherine Joseph,Walter Huber,(unknown),(unknown),Agnès Bénardeau,Marcel Gubler,Brigitte Schott,Effie Tozzo	25
14	Allosteric FBPase inhibitors gain 105 times in potency when simultaneously binding two neighboring AMP sites 2008 ·Bioorganic & Medicinal Chemistry Letters ·Paul Hebeisen,Bernd Kuhn,Philipp Köhler,Marcel Gubler,Walter Huber,Eric Kitas,Brigitte Schott,Jörg Benz,Catherine Joseph,A. Ruf	30
15	5-HT2C Receptor Agonists for the Treatment of Obesity. Biological and Chemical Adventures 2004 ·CHIMIA International Journal for Chemistry ·David Adams,Sven Taylor,Stephan Röver,Hans Richter,Jean‐Marc Plancher,Jacques Mizrahi,(unknown),Antony R. Knight,G.A. Kennett,Paul Hebeisen,Ian A. Cliffe,Anne Bourson,Caterina Bissantz,(unknown),Mike Bickerdike,Agnès Bénardeau,Steven P. Vickers	18
16	Concise Synthesis of Cyclothialidine Analogues (VI) with Ring Sizes from 12 to 15: Novel Macrocyclization Protocol Involving Reductive Thiolation. 2003 ·ChemInform ·(unknown),(unknown),Paul Hebeisen	1
17	New Anti-MRSA and Anti-VRE Carbapenems; Synthesis and Structure-activity Relationships of 1.BETA.-Metyl-2-(thiazol-2-ylthio)carbapenems. 2002 ·The Journal of Antibiotics ·Makoto Sunagawa,Masanori Itoh,Katsumi Kubota,Akira Sasaki,Yutaka Ueda,Peter Angehrn,Anne Bourson,(unknown),Paul Hebeisen,Rudolf Then	13
18	Cyclothialidine and its congeners: A new class of DNA gyrase inhibitors 1993 ·Pharmacology & Therapeutics ·(unknown),Peter Angehrn,Hans Gmuender,Paul Hebeisen,Helmut Link,Raffaello Masciadri,Jens Nielsen	42
19	Synthesis of bicyclic keto silanes by tandem rearrangement of silylacetylenic ketones 1988 ·Journal of the American Chemical Society ·Andrew S. Kende,Paul Hebeisen,(unknown)	11
20	Condensation of a p-diazooxide with dimethyl acetylenedicarboxylate: formation of a spiro [4.5] Decatetraenone and a nonenolizable naphthalenone in a single reaction 1985 ·Tetrahedron Letters ·Andrew S. Kende,Paul Hebeisen	8

About Paul Hebeisen

Paul Hebeisen is a scholar working on Organic Chemistry, Molecular Medicine and Toxicology, having authored 39 papers that have together received 968 indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (10 papers), Synthesis and Biological Evaluation (6 papers) and Cancer therapeutics and mechanisms (5 papers). The work is most often cited by research in Molecular Medicine (157 citations), Organic Chemistry (402 citations) and Toxicology (39 citations). Paul Hebeisen has collaborated with scholars based in Switzerland, Austria and Germany. Frequent co-authors include Peter Angehrn, Rudolf Then, Malcolm G. P. Page, Ingrid Heinze‐Krauss, P. Hohl, Matthias P. Wymann, Florent Beaufils, Chiara Borsari, Denise Rageot and Thomas Bohnacker. Their work appears in journals such as Journal of the American Chemical Society, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact